Document text
Principal Investigator: Elizabeth Ottinger
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2024
Award: $125,000
Funding agency: National Center for Advancing Translational Sciences
TDB has performed a number of repurposing screening efforts and the IND-directed development of GS-441524. The latter included drug metabolism and pharmacokinetic (PK) studies, human PK modeling, toxicology studies, drug product manufacture and formulation studies. TDB scientists are also contributing data and protocols to the Open Data Portal, a resource created by NCATS to house a collection of datasets generated from SARS-CoV-2-related assays performed at NCATS. This effort deposits COVID-19 related data in an open data-sharing platform to allow research scientists, clinical investigators and public health officials to prioritize promising compounds and repurposed drugs for further development in treating COVID-19
As part of the broader public health response to COVID-19, TDB scientists have participated in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, using SARS-CoV-2 pseudotyped particle (PP) entry assays to test the efficacies of vaccinated human sera against emerging SARS-CoV-2 spike protein variants. The surveillance of variant mutations and their impact on COVID-19 vaccines is a critical task that involves multiple government organizations. TDB scientists employed the PP entry assay to test the neutralization potency of SARS-CoV-2 vaccinated sera, including homologous and heterologous boosted sera, against more than 18 SARS-CoV-2 variants, including delta, omicron, and omicron subvariants. All the data have been quickly and openly disseminated using the NCATS OpenData Portal. This work has provided the NIH leadership, industry, academic partners, and the external research community with a comprehensive, standardized assessment of how current vaccines are impacted by emerging SARS-CoV-2 variants.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Acceleration><Assay><Bioassay><Biological Assay><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 years><COVID19 virus><CV-19><Clinical><Clinical Investigator><CoV-2><CoV2><Communities><Coronavirus Infectious Disease 2019><Data><Data Collection><Data Set><Deposit><Deposition><Development><Drug Kinetics><Drugs><Formulation><GS-441524><Genetic Alteration><Genetic Change><Genetic defect><Government><Human><Industry><Leadership><Medication><Modern Man><Mutation><NCATS><NIH><National Center for Advancing Translational Sciences><National Institutes of Health><Neutralization Tests><Pharmaceutical Preparations><Pharmacokinetics><Position><Positioning Attribute><Productivity><Protocol><Protocols documentation><Public Health><Research><Research Resources><Resources><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Standardization><Therapeutic Intervention><Toxicology><United States National Institutes of Health><Vaccinated><Vaccines><Variant><Variation><Viral Activity><Viral Function><Viral Physiology><Work><Wuhan coronavirus><antibody neutralization test><assay development><clinical candidate><clinical development><clinical efficacy><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><data portal><data sharing portal><developmental><drug development><drug metabolism><drug repositioning><drug repurposing><drug/agent><efficacy testing><genome mutation><hCoV19><intervention therapy><manufacture><model development><model developments><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><open data><open science><open-source data><particle><pharmacokinetic model><pre-clinical development><preclinical development><public-private partnership><repurposing agent><repurposing medication><response><screening><screenings><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><shareable platform><sharing platform><spike proteins on SARS-CoV-2><therapeutic agent development><therapeutic development><therapeutic vaccine><therapeutics against COVID-19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment vaccines><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine for the treatment><vaccine for treatment><vaccines preventing COVID><vaccines to prevent COVID>